Research ExplorerPublicationsLiquid biopsy and preclinical tools for advancing diagnosis ...

Liquid biopsy and preclinical tools for advancing diagnosis and treatment of patients with pancreatic neuroendocrine neoplasms

Standard

Liquid biopsy and preclinical tools for advancing diagnosis and treatment of patients with pancreatic neuroendocrine neoplasms. / Smolkova, Bozena; Kataki, Agapi; Earl, Julie; Ruz-Caracuel, Ignacio; Cihova, Marina; Urbanova, Maria; Buocikova, Verona; Tamargo, Sandra; Rovite, Vita; Niedra, Helvijs; Schrader, Joerg; Kohl, Yvonne.

In: CRIT REV ONCOL HEMAT, Vol. 180, 103865, 12.2022.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Smolkova, B, Kataki, A, Earl, J, Ruz-Caracuel, I, Cihova, M, Urbanova, M, Buocikova, V, Tamargo, S, Rovite, V, Niedra, H, Schrader, J & Kohl, Y 2022, 'Liquid biopsy and preclinical tools for advancing diagnosis and treatment of patients with pancreatic neuroendocrine neoplasms', CRIT REV ONCOL HEMAT, vol. 180, 103865. https://doi.org/10.1016/j.critrevonc.2022.103865

APA

Smolkova, B., Kataki, A., Earl, J., Ruz-Caracuel, I., Cihova, M., Urbanova, M., Buocikova, V., Tamargo, S., Rovite, V., Niedra, H., Schrader, J., & Kohl, Y. (2022). Liquid biopsy and preclinical tools for advancing diagnosis and treatment of patients with pancreatic neuroendocrine neoplasms. CRIT REV ONCOL HEMAT, 180, [103865]. https://doi.org/10.1016/j.critrevonc.2022.103865

Vancouver

Smolkova B, Kataki A, Earl J, Ruz-Caracuel I, Cihova M, Urbanova M et al. Liquid biopsy and preclinical tools for advancing diagnosis and treatment of patients with pancreatic neuroendocrine neoplasms. CRIT REV ONCOL HEMAT. 2022 Dec;180. 103865. https://doi.org/10.1016/j.critrevonc.2022.103865

Bibtex

@article{22b280a680cf43f1afb238f38d3f9dbb,
title = "Liquid biopsy and preclinical tools for advancing diagnosis and treatment of patients with pancreatic neuroendocrine neoplasms",
abstract = "Pancreatic neuroendocrine neoplasms (pNENs) are rare cancers with broad challenges for their management. The main clinical obstacles are the high rate of patients diagnosed at advanced stages, lack of prognostic markers for early detection of disease recurrence in resected patients, significant limitations in identifying those who will benefit from adjuvant therapy, and timely recognition of treatment response. Therefore, the discovery of new prognostic and predictive markers is necessary for patient stratification and clinical management. Liquid biopsy, which has revolutionized the field of clinical oncology, is extremely under-investigated in pNENs. This review highlights its potential and the recent advances in related technologies, as candidates for the delivery of the new tools that can help to refine pNEN diagnosis and to personalize treatment. In addition, the opportunities and limitations of available preclinical research models with regard to biomarker research are discussed in light of pNEN clinical needs.",
keywords = "Humans, Neuroendocrine Tumors/diagnosis, Pancreatic Neoplasms/diagnosis, Neoplasm Recurrence, Local, Liquid Biopsy, Prognosis",
author = "Bozena Smolkova and Agapi Kataki and Julie Earl and Ignacio Ruz-Caracuel and Marina Cihova and Maria Urbanova and Verona Buocikova and Sandra Tamargo and Vita Rovite and Helvijs Niedra and Joerg Schrader and Yvonne Kohl",
note = "Copyright {\textcopyright} 2022 The Authors. Published by Elsevier B.V. All rights reserved.",
year = "2022",
month = dec,
doi = "10.1016/j.critrevonc.2022.103865",
language = "English",
volume = "180",
journal = "CRIT REV ONCOL HEMAT",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

RIS

TY - JOUR

T1 - Liquid biopsy and preclinical tools for advancing diagnosis and treatment of patients with pancreatic neuroendocrine neoplasms

AU - Smolkova, Bozena

AU - Kataki, Agapi

AU - Earl, Julie

AU - Ruz-Caracuel, Ignacio

AU - Cihova, Marina

AU - Urbanova, Maria

AU - Buocikova, Verona

AU - Tamargo, Sandra

AU - Rovite, Vita

AU - Niedra, Helvijs

AU - Schrader, Joerg

AU - Kohl, Yvonne

N1 - Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.

PY - 2022/12

Y1 - 2022/12

N2 - Pancreatic neuroendocrine neoplasms (pNENs) are rare cancers with broad challenges for their management. The main clinical obstacles are the high rate of patients diagnosed at advanced stages, lack of prognostic markers for early detection of disease recurrence in resected patients, significant limitations in identifying those who will benefit from adjuvant therapy, and timely recognition of treatment response. Therefore, the discovery of new prognostic and predictive markers is necessary for patient stratification and clinical management. Liquid biopsy, which has revolutionized the field of clinical oncology, is extremely under-investigated in pNENs. This review highlights its potential and the recent advances in related technologies, as candidates for the delivery of the new tools that can help to refine pNEN diagnosis and to personalize treatment. In addition, the opportunities and limitations of available preclinical research models with regard to biomarker research are discussed in light of pNEN clinical needs.

AB - Pancreatic neuroendocrine neoplasms (pNENs) are rare cancers with broad challenges for their management. The main clinical obstacles are the high rate of patients diagnosed at advanced stages, lack of prognostic markers for early detection of disease recurrence in resected patients, significant limitations in identifying those who will benefit from adjuvant therapy, and timely recognition of treatment response. Therefore, the discovery of new prognostic and predictive markers is necessary for patient stratification and clinical management. Liquid biopsy, which has revolutionized the field of clinical oncology, is extremely under-investigated in pNENs. This review highlights its potential and the recent advances in related technologies, as candidates for the delivery of the new tools that can help to refine pNEN diagnosis and to personalize treatment. In addition, the opportunities and limitations of available preclinical research models with regard to biomarker research are discussed in light of pNEN clinical needs.

KW - Humans

KW - Neuroendocrine Tumors/diagnosis

KW - Pancreatic Neoplasms/diagnosis

KW - Neoplasm Recurrence, Local

KW - Liquid Biopsy

KW - Prognosis

U2 - 10.1016/j.critrevonc.2022.103865

DO - 10.1016/j.critrevonc.2022.103865

M3 - SCORING: Review article

C2 - 36334880

VL - 180

JO - CRIT REV ONCOL HEMAT

JF - CRIT REV ONCOL HEMAT

SN - 1040-8428

M1 - 103865

ER -